For your diary

A round-up of business events happening this week

Valeant names Papa as its new CEO

Joseph Papa confirms position day after he resigns from the top spot at drugmaker Perrigo

Oil price surge prompts optimism for energy companies, pushing markets ahead

Iseq rises as stocks on Wall Street and in Europe lifted by energy companies

Valeant gets extra month from lenders to file annual report

Canadian pharma company says it remains well positioned to meet its obligations

Pfizer and Allergan confirm end to $160bn merger

New rules on corporate inversions see parties turn their attention elsewhere

Valeant fails to satisfy investors in ‘female viagra’

Sprout shareholders say company has set price too high, not marketing pill properly

Shake-up at Valeant signals stunning fall from grace for J Michael Pearson

Pharmaceutical giant faces a growing list of questions from investors and regulators

Valeant says chief executive Michael Pearson to step down

Company has appointed activist investor William Ackman to its board

European shares led lower by commodity stocks

Iseq ends lower with Bank of Ireland, Applegreen and Aryzta among the fallers

Valeant Pharmaceuticals International cuts revenue forecast

The Canadian drugmaker cut its 2016 forecast by about 12% causing shares to plunge

Valeant shares plunge 45 per cent on debt default risk

Canadian drugmaker cuts its revenue forecast by 12% and raises the spectre of default

Valeant insists key executive resigned and was not asked to go

Deb Jorn oversaw the Canadian pharmaceutical’s US dermatology business

Valeant shares slump on new SEC investigation

News comes as Canadian drug-maker pulled 2016 forecasts

Drugmaker Valeant pulls forecasts as Pearson returns

Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post

Johnson & Johnson loses $72m ‘talcum powder’ cancer case

First damages award over claims firm knew of ovarian cancer risks decades ago, company still faces 1,200 suits

Shares in Canadian drugmaker Valeant decline steeply for second day running

Wall Street Journal reports that pharmaceutical firm plans to restate earnings

One More Thing: Ingram in Valeant hot seat

Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair

Ackman hedge fund sells down part of Valeant stake

Pershing Square Capital increased stake in beleaguered drug group last November but acts to generate tax loss for investors

Massive increases in medicine prices leave nasty taste

Pharma companies’ method of buying drug makers and racking up costs is a threat to R&D

Stocks in New York headed for best month in four years

Food group Aryzta’s shares drop again in Dublin following boardroom reshuffle

Joe Nocera: Valeant Pharmaceuticals looking like another Enron

Eye-popping growth and questionable acquisitions raise far too many questions

Markets surge on Draghi statements

ECB president’s signal that stimulus will continue gives boost to markets

Drug price query by US Democrats sees Valeant slide

Valeant Pharmaceuticals shares shed a further $4.30, or 2.58 per cent

Clinton wants price cap after 5,000% rise in drug cost

Treatment for parasitic infection a ‘bargain’ at $750 a tablet, says company executive

Company making ‘female Viagra’ sold to Valeant for $1bn

Deal comes days after final US approval for controversial drug

Valeant raises forecasts after topping expectations in first quarter

Fast-growing company loses CFO Howard Schiller as it looks to address issues with $11bn Salix Pharma acquisition

Generic drugmaker Teva makes $40bn offer for rival Mylan

Mylan adopts poison-pill defence and renews commitment to Perrigo deal

Europe rallies but Iseq finishes down

European stock markets continue to enjoy lift from ECB’s quantitative easing

Salix accepts takeover offer from Valeant

Pharma group accepts higher bid as Dublin based bidder Endo withdraws

Bausch & Lomb to create 50 new posts in Waterford

Contact lens maker is to invest €41m in its Waterford facility over the next 18 months

Actavis pays $66bn for botox maker Allergan

Largest M&A deal of 2014 sees off hostile attention from rival Valeant

Allergan says it has been approached by another party

Actavis rumoured to be going head-to-head with rival Valeant for botox and eyecare group

Valeant to raise Allergan bid to at least $200 a share

Pharmaceutical firm’s offer values the Botox maker at $53bn

Allergan shareholder Paulson & Co urges deal with Shire

Shareholders are looking at alternative strategies for Allergan as it tries to fend off a deal from Valeant

Ireland’s Endo to buy Auxilium for $2.6bn to gain testosterone products

Share price represents premium of 55 per cent

Shareholder advisory firm calls for vote on aquisitions at Allergan

Botox maker’s board faces credibility problem, says ISS

Ukraine violence weighs on global markets

Late afternoon sell-off sees Bank of Ireland shares fall more than 4%

Allergan to cut 1,500 jobs as it fights off bid from Valeant

Company announces $475 million restructuring meant to boost profits over six years

Allergan wins US approval for diabetic vision-loss treatment

Migraine inhaler fails to secure go-ahead, with FDA citing delivery issues

Advisers on pursuit of Allergan pitch out of both sides of mouth

Cantillon: few ‘clean hands’ in investment banking

Valeant’s unsolicited bid for Allergan part of a cheeky business model

Valeant Pharmaceuticals is a drug company that doesn’t develop drugs – it runs a serial takeover operation

YOU MAY ALSO LIKE...

Stardust

Inquests into the nightclub fire that led to the deaths of 48 people

Common Ground

How does a post-Brexit world shape the identity and relationship of these islands